Invokana, Farxiga, and Similar Diabetes Drugs Effective, But Carry Genital Infection Risk: Study
A new study links Invokana, Farxiga and similar diabetes drugs to an increased risk of genital infections.
A new study links Invokana, Farxiga and similar diabetes drugs to an increased risk of genital infections.
A new study links some diabetes drugs to an increased risk of gallbladder disease.
A new study reveals rampant overtreatment of nursing home residents with type 2 diabetes is resulting in patients with dangerously low blood sugar levels.
A federal judge has again dismissed hundreds of diabetes drug lawsuits alleging medications like Byetta and Januvia can cause pancreatic cancer.
A new study raises questions about FDA findings that Invokana and similar diabetes drugs can increase the risk of bone fractures.
A new study appears to confirm FDA warnings that Invokana and similar diabetes drugs increase the risk of diabetic ketoacidosis in type 2 diabetes patients.
Public Citizen has petitioned the FDA to add black box warnings to Invokana and similar drugs, contraindicating their use by Type 1 diabetics due to the risk of diabetic ketoacidosis.
A new study finds that diabetes drugs like Invokana are less likely to cause kidney problems than drugs like Onglyza and Januvia.
A new study questions the decision of the FDA to place acute kidney injury warnings on Invokana and similar diabetes drugs.
A draft guidance seeks to require broader clinical trials for diabetes drugs, in an effort to better identify potential adverse health effects before they receive FDA approval.